1. Pharmacodynamic and DNA methylation studies of high-dose 1-β-d-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia

   • Vassilios I. Avramis
   • Robert A. Mecum
   • John S. Holcenberg

   Original Articles Pages: 203 - 210

2. The relative toxicity of intravenous and intraperitoneal doses of epirubicin

   • T. K. Yeung
   • R. H. Simmonds
   • J. W. Hopewell

   Original Articles Pages: 211 - 218

3. Activity of the pyrazoloacridines against multidrug-resistant tumor cells

   • Judith Sebolt
   • Martha Havlick
   • Robert Jackson

   Original Articles Pages: 219 - 224

4. Comparison of the intracellular pharmacokinetics of doxorubicin and 4′-epi-doxorubicin in patients with acute leukemia

   • Ulf Tidefelt
   • Britt Sundman-Engberg
   • Christer Paul

   Original Articles Pages: 225 - 229

5. Evaluation of an amsacrine analog in a human tumor cloning system

   • Bernd Lathan
   • Daniel D. Von Hoff
   • Edward E. Elslager

   Original Articles Pages: 230 - 232

6. Phase I clinical and pharmacokinetic study of LY 195448

   • James Cassidy
   • Craig Lewis
   • Stanley B. Kaye

   Original Articles Pages: 233 - 237

7. The effect of structural modifications of 5-fluorouracil derivatives on their transport and biodegradation by isolated rat jejunum

   • Ladislav Novotný
   • Hassan Farghali
   • Jiří Beránek

   Original Articles Pages: 238 - 242

8. Severe renal toxicity due to intermediate-dose methotrexate

   • Allistair N. Stark
   • Graham Jackson
   • Stephen J. Proctor

   Original Articles Pages: 243 - 245

9. A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion

   • James F. Bishop
   • Derek Raghavan
   • Michael L. Friedlander

   Original Articles Pages: 246 - 250

10. A study of the mechanisms of cytotoxicity of Ara-C on three human leukemic cell lines

    • J. Zittoun
    • J. Marquet
    • R. Zittoun

    Original Articles Pages: 251 - 255

11. Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer

    • Phillip A. Reece
    • Irene Stafford
    • Susan Freeman

    Original Articles Pages: 256 - 260

12. Phase II study with etoposide in previously untreated advanced breast cancer

    • Hans-Erik Wander
    • Winrich Rauschning
    • Gerd-Arno Nagel

    Original Articles Pages: 261 - 263

13. The cytotoxicity of T-2 toxin and related 12,13-epoxytrichothecenes to Adriamycin-sensitive and-resistant P388 leukemia cells

    • Avner Ramu
    • Boris Yagen
    • Nili Ramu

    Short Communication Pages: 264 - 267

14. Paul A. J. Speth, M.D.

    • Paul Workman

    Obituary Pages: 268 - 268